

Supplementary Data

Elevated Levels of High-Sensitivity C-Reactive Protein are Associated with Mild Cognitive Impairment and its Subtypes: Results of a Population-Based Case-Control Study

Martha Dlugaj^{a,*}, Marcus Gerwig^a, Natalia Wege^b, Johannes Siegrist^b, Klaus Mann^c, Martina Bröcker-Preuß^d, Nico Draganò^e, Susanne Moebus^e, Karl-Heinz Jöckel^e, Beate Bokhof^e, Stefan Möhlenkamp^f, Raimund Erbel^f, Christian Weimar^a and on behalf of the Heinz Nixdorf Recall Study Investigative Group

^aDepartment of Neurology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany

^bDepartment of Medical Sociology, University of Düsseldorf, Düsseldorf, Germany

^cDepartment of Endocrinology, University Hospital of Essen, University Duisburg-Essen, Essen, Germany

^dDepartment of Endocrinology, Division of Laboratory Research, University Hospital of Essen, University Duisburg-Essen, Essen, Germany

^eInstitute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg-Essen, Essen, Germany

^fClinic of Cardiology, West German Heart Centre, University Hospital of Essen, University Duisburg-Essen, Essen, Germany

Accepted 20 September 2011

*Correspondence to: Martha Dlugaj, Dipl.-Psych., University Hospital Essen, Department of Neurology, Hufelandstr. 55, 45147 Essen, Germany. Tel.: +49 201 723 2588; Fax: +49 201 723 5953; E-mail: Martha.Dlugaj@uk-essen.de.

Supplementary Table 1
Cardiovascular risk factors in amnesic and non-amnesic MCI participants at baseline and five years follow-up

	Baseline examination			Follow-up examination		
	aMCI <i>n</i> = 106	naMCI <i>n</i> = 42	<i>p</i> value	aMCI <i>n</i> = 106	NaMCI <i>n</i> = 42	<i>p</i> value
HsCRP, mg/l [†]	2.81 ± 2.36	2.56 ± 2.62	0.58	2.68 ± 2.19	2.26 ± 1.38	0.18
Q1 (≤0.78/≤0.90)	17 (17)	10 (25)		23 (22)	7 (17)	
Q2 (>0.78–1.70/>0.90–1.74)	29 (29)	11 (28)	0.73	21 (21)	12 (29)	0.61
Q3 (>1.70–3.33/>1.74–3.30)	26 (26)	10 (25)		25 (26)	11 (27)	
Q4 (>3.33/>3.30)	28 (28)	11 (22)		34 (33)	11 (27)	
BMI, kg/m ²	29 ± 4.5	28.3 ± 4.3	0.44	29.1 ± 4.8	29.1 ± 4.8	0.98
Overweight (25–29)	48 (46)	25 (60)	0.23	51 (49)	21 (50)	0.78
Obese (>30)	40 (38)	10 (24)		41 (39)	14 (33)	
Waist-to-hip ratio (WHR)	0.94 ± 0.08	0.92 ± 0.1	0.14	0.96 ± 0.09	0.95 ± 0.1	0.64
Overweight	38 (36)	13 (31)	0.22	31 (30)	14 (33)	0.57
Obese	61 (59)	23 (55)		69 (66)	24 (57)	
Lipids						
Total cholesterol, mg/dl	222.9 ± 40.2	232.1 ± 46.2	0.23	214 ± 38.3	223.9 ± 52.8	0.21
LDL cholesterol, mg/dl	141.5 ± 38.3	152.1 ± 41.4	0.14	125.7 ± 33.8	131.9 ± 38.8	0.34
HDL cholesterol mg/dl	54.4 ± 15.1	58 ± 18.2	0.43	55.9 ± 15.6	56.3 ± 13.6	0.91
Lipoprotein a, mg/dl	19.8 ± 22.3	26.2 ± 34.2	0.60	23.1 ± 28.2	28.2 ± 39.6	0.89
Triglycerides, mg/dl	166.9 ± 94.3	147 ± 71.4	0.39	140.1 ± 72.1	146.1 ± 67.9	0.51
Total cholesterol ≥240 mg/dl	39 (37)	16 (38)	0.88	25 (61)	14 (33)	0.24
Intake of lipid lowering drugs	17 (16)	5 (12)	0.56	24 (23)	10 (24)	0.88
Blood pressure						
Systolic blood pressure, mmHg	139 ± 19.3	128.4 ± 16.3	0.002	139.9 ± 22.9	130.6 ± 20.2	0.025
Diastolic blood pressure, mmHg	80.1 ± 9.5	80.6 ± 10.4	0.77	78.1 ± 11.6	77.3 ± 9.9	0.71
Prevalence of hypertension						
JNC 7 stage 1	36 (34)	8 (19)	0.039	26 (63)	12 (29)	0.22
JNC 7 stage 2	16 (15)	3 (7)		20 (49)	3 (7)	
Smoking status						
Never smoked	53 (50)	17 (40)	0.13	53 (50)	17 (40)	0.33
Former smoker	36 (34)	12 (29)		39 (37)	16 (38)	
Current smoker	17 (16)	13 (31)		14 (13)	9 (22)	
Diabetes mellitus	25 (24)	7 (17)	0.36	33 (31)	10 (24)	0.38
Glucose, mg/dl	117.5 ± 32.3	112.8 ± 23.8	0.57	118.9 ± 27.8	115.9 ± 24.9	0.64
HbA1c, %	5.7 ± 1.1	5.8 ± 0.7	0.11	5.9 ± 0.8	5.6 ± 1.2	0.71
History of stroke	4 (4)	1 (2)	0.66	7 (7)	2 (5)	0.67
History of coronary heart disease	13 (12)	7 (17)	0.49	14 (13)	7 (17)	0.59
Intake of NSAIDs drugs	12 (11)	7 (17)	0.34	18 (17)	7 (17)	0.96
Uric acid, mg/dl	5.7 ± 1.5	5.7 ± 1.3	0.99	5.8 ± 1.4	5.7 ± 1.3	0.51
Pure alcohol intake, g/week	49.2 ± 92.6	34.1 ± 81.7	0.11	40 ± 72.1	26.5 ± 52.3	0.58
APOE genotype ^{††}						
ε2/ε2	1 (1)	0 (0)				
ε2/ε3	10 (10)	3 (7)				
ε2/ε4	6 (6)	0 (0)				
ε3/ε3	58 (59)	30 (73)	0.45			
ε3/ε4	23 (23)	8 (20)				
ε4/ε4	1 (1)	0 (0)				
APOE ε4 ^{††}						
ε4 positive	30 (30)	8 (19)	0.14			
ε4 negative	69 (70)	33 (81)				

Data are presented as means (±SD) or as numbers (%) unless otherwise indicated. Significant p-values are presented in bold. aMCI = amnesic mild cognitive impairment; naMCI = non-amnesic mild cognitive impairment; hsCRP = high sensitivity C-reactive protein; BMI = body mass index; Waist-to-hip ratio (WHR: overweight: women 0.8–0.84; men 0.9–0.99; obese: women >0.85; men >1.0); LDL = low-density lipoprotein; HDL = high-density lipoprotein; JNC 7 = Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: stage 1 = 140–159 mmHg, stage 2 ≥ 160 mmHg; HbA1c = Hemoglobin A1c; NSAID = non-steroidal anti-inflammatory drugs; Q_{1/2/3/4} = Quartile (1/2/3/4); ε4 positive = at least one ε4 allele (ε2/ε4, ε3/ε4, ε4/ε4); [†]*n* = 8 (baseline) and *n* = 11 (follow-up) MCI participants were excluded because of hsCRP >10 mg/l; ^{††}genotyping not available for *n* = 8 participants (7 aMCI/1 naMCI).